J Dermatolog Treat. 2017 Aug 7:1-19. doi: 10.1080/09546634.2017.1365115. [Epub ahead of print]
Rutherford A1, Glass DA 2nd1,2,3, Suarez EA4, Adamson AS1,5,6.
Pateints avoid non-vitamin D dermatologic prescriptions
Wonder when dermatologists are going to learn?
- Dermatologists still not convienced that Vitamin D reduces atopic dermatitis – Review Dec 2013
- Psoriasis proven to be treated by Vitamin D in many RCT, but dermatologists fear losing business – March 2015
- Sunburning reduced by 200,000 IU of Vitamin D – RCT April 2017
- Atopic dermatitis reduced with 1600 IU of vitamin D plus vitamin E – July 2011
- Ultraviolet light (which produces vitamin D) decreased the use of psoriasis drugs for a year – Aug 2017
- Why are doctors reluctant to accept vitamin D
#10: "It is difficult to get a man to understand something when his salary is dependent upon his not understanding it”
To analyze factors associated with primary nonadherence to dermatologic medications and study whether prescription-level factors are associated with primary nonadherence.
MATERIAL AND METHODS:
A retrospective review of medical records of new dermatology patients from January 2011 to December 2013 at a single urban safety-net hospital outpatient dermatology clinic with a closed pharmacy system.
A total of 4307 prescriptions were written for 2490 patients. The overall primary nonadherence rate was 24.7%. The most prescribed medication classes in order of frequency were topical corticosteroids, topical antibiotics, topical retinoids, oral antibiotics, and topical antifungals. After multivariable adjustment for patient, provider, and prescription characteristics, when compared to topical corticosteroids, topical antibiotics, oral antifungals, and oral antivirals were less likely to be filled (RR 0.9 [95% CI, 0.84-0.95]), (RR 0.69 [95% CI, 0.59-0.81]), and (RR 0.65 [95% CI, 0.46-0.93]), respectively.
Conversely, topical vitamin D analogs, oral immunomodulators, and oral retinoids were more likely to be filled (RR 1.15 [95% CI, 1.02-1.28]), (RR 1.11 [95% CI, 1.04-1.19]), and (RR 1.15 [95% CI, 1.04-1.27]), respectively.
Medication class or administration route may be associated with increased risk of nonadherence, and identifying these factors is important in considering ways to reduce primary nonadherence rates in dermatology.
PMID: 28783420 DOI: 10.1080/09546634.2017.1365115